• <code id="kgams"><tr id="kgams"></tr></code>
    <abbr id="kgams"></abbr>
  • <abbr id="kgams"></abbr>
    Home
    Who We Are
    What We Do
    Corporate Responsibility
    News
    Careers
    Investors
    Patients and HCPS
    Contact us
    Careers | Investors | Patients and HCPS | Contact us
    Careers Investors Patients and HCPS Contact us
    Home / Company News / Gan & Lee Pharmaceuticals Announces Approval of Insulin Aspart Injection in Bolivia
    Gan & Lee Pharmaceuticals Announces Approval of Insulin Aspart Injection in Bolivia
    Date:2024-01-26

    Beijing, China, January 26, 2024 - Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087. SH) recently announced that its insulin aspart injection has been approved for the treatment of diabetes by the Agencia Estatal de Medicamentos y Tecnologías en Salud (AGEMED) of Bolivia. This is another achievement following the previous approval of Gan & Lee's insulin glargine injection. The approval signifies Gan & Lee as a marketing authorization holder (MAH) for insulin aspart injection in Bolivia, granting the company the official commercial license to sell the product in the country. This milestone also marks the company’s first success in introducing its insulin aspart to the Latin American region.

     

    Bolivia, located in central South America, has a total population of 12.22 million (2022), with a per capita GDP of $3,600.1(2022, international exchange rate). According to the latest data from the International Diabetes Federation (IDF) Atlas, 10th edition (2021), approximately 395,900 people aged 20-79 years were reported to have diabetes in Bolivia in 2021. The average annual diabetes-related expenditure per patient was $898.8. The prevalence of diabetes in the adult population aged 20-79 years in Bolivia was 5.7%.2


    In Bolivia, the primary supplier of insulin aspart injections was the originator, Novo Nordisk. Gan & Lee's insulin aspart product is the first biosimilar insulin aspart approved in the country, which means we have broken the market monopoly and introduced a high-quality, low-cost biosimilar medicine to Bolivia. This move enriches the local diabetes treatment options and provides a cost-effective alternative for people with diabetes in Bolivia.


    Drawing on years of experience in overseas market development and international resources, Gan & Lee continues to strengthen its commercial network in countries along the "Belt and Road". Bolivia is a participant in the "Belt and Road" initiative and is also one of the target countries in Gan & Lee Pharmaceuticals' “going global” strategy. The approval marks a crucial step in Gan & Lee's commitment to its global strategy, providing multiple treatment options for diabetes patients in Bolivia. This move is in line with the company's efforts to contribute to the globalization of healthcare solutions and reflects the broader vision of improving access to healthcare for diabetes patients in the region.


    References:

    1.     The World Bank. (2024). Bolivia. The World Bank. Retrieved January 25, 2024, from https://data.worldbank.org/country/bolivia

    2.     IDF Diabetes Atlas 10th edition 2021. Available

    at: https://diabetesatlas.org/atlas/tenth-edition/

    cost-effeciions and provides an


    About Gan & Lee

    Gan & Lee Pharmaceuticals has developed the first Chinese domestic biosynthetic human insulin. Currently, we have six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin?), fast-acting lispro injection (Prandilin?), fast-acting aspart injection (Rapilin?), mixed protamine zinc lispro injection (25R) (Prandilin?25), aspart 30 injection (Rapilin?30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin?30). We have two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine?).

     

    In the future, Gan & Lee strives to achieve a comprehensive coverage in the field of diabetes diagnosis and treatment. Moving forward to advance our goal of becoming a world-class pharmaceutical company, we will also take an active part in developing new chemical entities, and work on the treatment of cardiovascular diseases, metabolic diseases, cancer, and other therapeutics.

     


    Copyright ? 2021 Gan & Lee Pharmaceuticals. All Rights Reserved. 京ICP備10213074號-1 | 京公網(wǎng)安備 11011202003900號
    Our websites

    Subscribe

    I read, agree with and accept all of the Privacy Policy and Terms of Use of this website.
    主站蜘蛛池模板: 国产口爆吞精在线视频| 最新无码a∨在线观看| 奇米影视四色中文字幕| 制服丝袜中文字幕在线| 中国极品美軳免费观看| 色吊丝永久性观看网站大全| 日本护士恋夜视频免费列表| 国产三级电影免费观看| 久久九九久精品国产| 草莓视频在线免费| 扒下胸罩揉她的乳尖调教| 啊轻点灬大巴太粗太长视频| 两性高清性色生活片性高清←片 | 久久久久国产视频| 青娱乐国产视频| 无翼乌全彩无漫画大全| 国产精品丝袜黑色高跟鞋| 伊人久久大线蕉香港三级| h视频在线观看免费网站| 狠狠人妻久久久久久综合蜜桃| 日日噜噜噜夜夜爽爽狠狠视频| 国产v在线在线观看羞羞答答| 亚洲sss视频| 黄页网址在线观看| 日日夜夜精品视频| 午夜在线亚洲男人午在线| jiuma啊灬啊别停灬啊灬快点| 波霸女的湮欲生活mp4| 国产精品女上位在线观看| 亚洲精品视频在线观看视频| 一级黄色在线播放| 看欧美黄色大片| 小说区乱图片区| 亚洲精品福利在线观看| 福利网址在线观看| 日本高清无卡码一区二区久久| 国产一区二区三区在线观看视频 | 中文字幕热久久久久久久| 精品久久久久久无码中文野结衣| 大尺度无遮挡h彩漫| 人妻在线日韩免费视频|